{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T12:36:23Z","timestamp":1791203783838,"version":"4.2.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2011,5,9]],"date-time":"2011-05-09T00:00:00Z","timestamp":1304899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2011,5,9]],"date-time":"2011-05-09T00:00:00Z","timestamp":1304899200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2012,4]]},"DOI":"10.1038\/bmt.2011.104","type":"journal-article","created":{"date-parts":[[2011,5,9]],"date-time":"2011-05-09T10:48:47Z","timestamp":1304938127000},"page":"581-588","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Sirolimus and mycophenolate mofetil as GVHD prophylaxis in myeloablative, matched-related donor hematopoietic cell transplantation"],"prefix":"10.1038","volume":"47","author":[{"given":"L","family":"Johnston","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Florek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Armstrong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J S","family":"McCune","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Arai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Laport","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Lowsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Miklos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Shizuru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Sheehan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Lavori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Negrin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,5,9]]},"reference":[{"key":"BFbmt2011104_CR1","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1097\/00007890-200110150-00001","volume":"72","author":"BD Kahan","year":"2001","unstructured":"Kahan BD, Camardo JS . Rapamycin: clinical results and future opportunities. Transplantation 2001; 72: 1181\u20131193.","journal-title":"Transplantation"},{"key":"BFbmt2011104_CR2","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1097\/00007890-200112270-00010","volume":"72","author":"AI Benito","year":"2001","unstructured":"Benito AI, Furlong T, Martin PJ, Anasetti C, Appelbaum FR, Doney K et al. Sirolimus (rapamycin) for the treatment of steroid-refractory acute graft-versus-host disease. Transplantation 2001; 72: 1924\u20131929.","journal-title":"Transplantation"},{"key":"BFbmt2011104_CR3","doi-asserted-by":"crossref","first-page":"3108","DOI":"10.1182\/blood-2006-09-046219","volume":"109","author":"C Cutler","year":"2007","unstructured":"Cutler C, Li S, Ho VT, Koreth J, Alyea E, Soiffer RJ et al. Extended follow-up of methotrexate-free immunosuppression using sirolimus and tacrolimus in related and unrelated donor peripheral blood stem cell transplantation. Blood 2007; 109: 3108\u20133114.","journal-title":"Blood"},{"key":"BFbmt2011104_CR4","first-page":"176","volume-title":"Hematopoietic Cell Transplantation","author":"NJ Chao","year":"1999","unstructured":"Chao NJ . Pharmacology and use of immunosuppressive agents after hematopoietic cell transplantation. In: Thomas E, Blume K, Forman S (eds) Hematopoietic Cell Transplantation, 2nd edn. Blackwell: Malden, MA, 1999 pp 176\u2013185."},{"key":"BFbmt2011104_CR5","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.bbmt.2005.02.006","volume":"11","author":"C Cutler","year":"2005","unstructured":"Cutler C, Li S, Kim HT, Laglenne P, Szeto KC, Hoffmeister L et al. Mucositis after allogeneic hematopoietic stem cell transplantation: a cohort study of methotrexate- and non-methotrexate-containing graft-versus-host disease prophylaxis regimens. Biol Blood Marrow Transplant 2005; 11: 383\u2013388.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2011104_CR6","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1182\/blood-2007-01-069294","volume":"110","author":"FM Marty","year":"2007","unstructured":"Marty FM, Bryar J, Browne SK, Schwarzberg T, Ho VT, Bassett IV et al. Sirolimus-based graft-versus-host disease prophylaxis protects against cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation: a cohort analysis. Blood 2007; 110: 490\u2013500.","journal-title":"Blood"},{"key":"BFbmt2011104_CR7","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1111\/j.1365-2141.2005.05616.x","volume":"130","author":"DR Couriel","year":"2005","unstructured":"Couriel DR, Saliba R, Escalon MP, Hsu Y, Ghosh S, Ippoliti C et al. Sirolimus in combination with tacrolimus and corticosteroids for the treatment of resistant chronic graft-versus-host disease. Br J Haematol 2005; 130: 409\u2013417.","journal-title":"Br J Haematol"},{"key":"BFbmt2011104_CR8","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.bbmt.2005.04.007","volume":"11","author":"C Cutler","year":"2005","unstructured":"Cutler C, Henry NL, Magee C, Li S, Kim HT, Alyea E et al. Sirolimus and thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2005; 11: 551\u2013557.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2011104_CR9","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.bbmt.2004.10.004","volume":"11","author":"LJ Johnston","year":"2005","unstructured":"Johnston LJ, Brown J, Shizuru JA, Stockerl-Goldstein KE, Stuart MJ, Blume KG et al. Rapamycin (sirolimus) for treatment of chronic graft-versus-host disease. Biol Blood Marrow Transplant 2005; 11: 47\u201355.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2011104_CR10","doi-asserted-by":"publisher","first-page":"4425","DOI":"10.1182\/blood-2008-07-169342","volume":"112","author":"C Cutler","year":"2008","unstructured":"Cutler C, Stevenson K, Kim HT, Richardson P, Ho VT, Linden E et al. Sirolimus is associated with veno-occlusive disease of the liver after myeloablative allogeneic stem cell transplantation. Blood 2008; 112: 4425\u20134431.","journal-title":"Blood"},{"issue":"2 Suppl","key":"BFbmt2011104_CR11","doi-asserted-by":"publisher","first-page":"S181","DOI":"10.1097\/01.tp.0000186390.10150.66","volume":"80","author":"AC Allison","year":"2005","unstructured":"Allison AC, Eugui EM . Mechanisms of action of mycophenolate mofetil in preventing acute and chronic allograft rejection. Transplantation 2005; 80 (2 Suppl): S181\u2013S190.","journal-title":"Transplantation"},{"key":"BFbmt2011104_CR12","doi-asserted-by":"publisher","first-page":"3729","DOI":"10.1016\/j.transproceed.2005.09.129","volume":"37","author":"O Bestard","year":"2005","unstructured":"Bestard O, Cruzado JM, Grinyo JM . Calcineurin-inhibitor-sparing immunosuppressive protocols. Transplant Proc 2005; 37: 3729\u20133732.","journal-title":"Transplant Proc"},{"issue":"2 Suppl","key":"BFbmt2011104_CR13","doi-asserted-by":"publisher","first-page":"S191","DOI":"10.1097\/01.tp.0000187035.22298.ba","volume":"80","author":"G Ciancio","year":"2005","unstructured":"Ciancio G, Miller J, Gonwa TA . Review of major clinical trials with mycophenolate mofetil in renal transplantation. Transplantation 2005; 80 (2 Suppl): S191\u2013S200.","journal-title":"Transplantation"},{"issue":"2 Suppl","key":"BFbmt2011104_CR14","doi-asserted-by":"publisher","first-page":"S211","DOI":"10.1097\/01.tp.0000186379.15301.e5","volume":"80","author":"TR Srinivas","year":"2005","unstructured":"Srinivas TR, Kaplan B, Schold JD, Meier-Kriesche HU . The impact of mycophenolate mofetil on long-term outcomes in kidney transplantation. Transplantation 2005; 80 (2 Suppl): S211\u2013S220.","journal-title":"Transplantation"},{"key":"BFbmt2011104_CR15","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/sj.bmt.1701281","volume":"22","author":"N Basara","year":"1998","unstructured":"Basara N, Blau WI, Romer E, Rudolphi M, Bischoff M, Kirsten D et al. Mycophenolate mofetil for the treatment of acute and chronic GVHD in bone marrow transplant patients. Bone Marrow Transplant 1998; 22: 61\u201365.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2011104_CR16","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1097\/00007890-199902270-00001","volume":"67","author":"M Bornhauser","year":"1999","unstructured":"Bornhauser M, Schuler U, Porksen G, Naumann R, Geissler G, Thiede C et al. Mycophenolate mofetil and cyclosporine as graft-versus-host disease prophylaxis after allogeneic blood stem cell transplantation. Transplantation 1999; 67: 499\u2013504.","journal-title":"Transplantation"},{"key":"BFbmt2011104_CR17","doi-asserted-by":"publisher","first-page":"2922","DOI":"10.1016\/S0041-1345(02)03489-9","volume":"34","author":"MG Kiehl","year":"2002","unstructured":"Kiehl MG, Schafer-Eckart K, Kroger M, Bornhauser M, Basara N, Blau IW et al. Mycophenolate mofetil for the prophylaxis of acute graft-versus-host disease in stem cell transplant recipients. Transplant Proc 2002; 34: 2922\u20132924.","journal-title":"Transplant Proc"},{"key":"BFbmt2011104_CR18","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1038\/sj.bmt.1704956","volume":"35","author":"F Neumann","year":"2005","unstructured":"Neumann F, Graef T, Tapprich C, Vaupel M, Steidl U, Germing U et al. Cyclosporine A and mycophenolate mofetil vs cyclosporine A and methotrexate for graft-versus-host disease prophylaxis after stem cell transplantation from HLA-identical siblings. Bone Marrow Transplant 2005; 35: 1089\u20131093.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2011104_CR19","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.bbmt.2005.03.006","volume":"11","author":"RA Nash","year":"2005","unstructured":"Nash RA, Johnston L, Parker P, McCune JS, Storer B, Slattery JT et al. A phase I\/II study of mycophenolate mofetil in combination with cyclosporine for prophylaxis of acute graft-versus-host disease after myeloablative conditioning and allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2005; 11: 495\u2013505.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2011104_CR20","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1038\/sj.bmt.1704647","volume":"34","author":"B Bolwell","year":"2004","unstructured":"Bolwell B, Sobecks R, Pohlman B, Andresen S, Rybicki L, Kuczkowski E et al. A prospective randomized trial comparing cyclosporine and short course methotrexate with cyclosporine and mycophenolate mofetil for GVHD prophylaxis in myeloablative allogeneic bone marrow transplantation. Bone Marrow Transplant 2004; 34: 621\u2013625.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2011104_CR21","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/j.bbmt.2006.04.009","volume":"12","author":"VH Nguyen","year":"2006","unstructured":"Nguyen VH, Zeiser R, Negrin RS . Role of naturally arising regulatory T cells in hematopoietic cell transplantation. Biol Blood Marrow Transplant 2006; 12: 995\u20131009.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2011104_CR22","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1016\/j.bbmt.2006.02.009","volume":"12","author":"LY Law","year":"2006","unstructured":"Law LY, Horning SJ, Wong RM, Johnston LJ, Laport GG, Lowsky R et al. High-dose carmustine, etoposide, and cyclophosphamide followed by allogeneic hematopoietic cell transplantation for non-Hodgkin lymphoma. Biol Blood Marrow Transplant 2006; 12: 703\u2013711.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2011104_CR23","first-page":"324","volume":"3","author":"GD Long","year":"1997","unstructured":"Long GD, Amylon MD, Stockerl-Goldstein KE, Negrin RS, Chao NJ, Hu WW et al. Fractionated total-body irradiation, etoposide, and cyclophosphamide followed by allogeneic bone marrow transplantation for patients with high-risk or advanced-stage hematological malignancies. Biol Blood Marrow Transplant 1997; 3: 324\u2013330.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2011104_CR24","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1038\/bmt.2010.114","volume":"46","author":"S Naik","year":"2011","unstructured":"Naik S, Wong R, Arai S, Brown J, Laport G, Lowsky R et al. Long-term outcomes in patients with high-risk myeloid malignancies following matched related donor hematopoietic cell transplantation with myeloablative conditioning of BU, etoposide and CY. Bone Marrow Transplant 2011; 46: 192\u2013199.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2011104_CR25","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.bbmt.2005.06.001","volume":"11","author":"VT Ho","year":"2005","unstructured":"Ho VT, Cutler C, Carter S, Martin P, Adams R, Horowitz M et al. Blood and marrow transplant clinical trials network toxicity committee consensus summary: thrombotic microangiopathy after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2005; 11: 571\u2013575.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2011104_CR26","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1097\/00007890-198712000-00011","volume":"44","author":"RJ Jones","year":"1987","unstructured":"Jones RJ, Lee KS, Beschorner WE, Vogel VG, Grochow LB, Braine HG et al. Venoocclusive disease of the liver following bone marrow transplantation. Transplantation 1987; 44: 778\u2013783.","journal-title":"Transplantation"},{"key":"BFbmt2011104_CR27","first-page":"825","volume":"15","author":"D Przepiorka","year":"1995","unstructured":"Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J et al. 1994 consensus conference on acute GVHD grading. Bone Marrow Transplant 1995; 15: 825\u2013828.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2011104_CR28","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/j.bbmt.2005.09.004","volume":"11","author":"AH Filipovich","year":"2005","unstructured":"Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005; 11: 945\u2013956.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2011104_CR29","doi-asserted-by":"publisher","first-page":"4381","DOI":"10.1182\/blood-2005-06-2217","volume":"106","author":"L Giaccone","year":"2005","unstructured":"Giaccone L, McCune JS, Maris MB, Gooley TA, Sandmaier BM, Slattery JT et al. Pharmacodynamics of mycophenolate mofetil after nonmyeloablative conditioning and unrelated donor hematopoietic cell transplantation. Blood 2005; 106: 4381\u20134388.","journal-title":"Blood"},{"key":"BFbmt2011104_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","volume":"10","author":"R Simon","year":"1989","unstructured":"Simon R . Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989; 10: 1\u201310.","journal-title":"Control Clin Trials"},{"key":"BFbmt2011104_CR31","doi-asserted-by":"publisher","first-page":"458","DOI":"10.4161\/cc.7.4.5454","volume":"7","author":"R Zeiser","year":"2008","unstructured":"Zeiser R, Negrin RS . Interleukin-2 receptor downstream events in regulatory T cells: implications for the choice of immunosuppressive drug therapy. Cell Cycle 2008; 7: 458\u2013462.","journal-title":"Cell Cycle"},{"key":"BFbmt2011104_CR32","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1097\/00007890-199810270-00013","volume":"66","author":"BD Kahan","year":"1998","unstructured":"Kahan BD, Podbielski J, Napoli KL, Katz SM, Meier-Kriesche HU, Van Buren CT . Immunosuppressive effects and safety of a sirolimus\/cyclosporine combination regimen for renal transplantation. Transplantation 1998; 66: 1040\u20131046.","journal-title":"Transplantation"},{"issue":"5 Part 1","key":"BFbmt2011104_CR33","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1111\/j.1600-6143.2006.01282.x","volume":"6","author":"S Kuppahally","year":"2006","unstructured":"Kuppahally S, Al-Khaldi A, Weisshaar D, Valantine HA, Oyer P, Robbins RC et al. Wound healing complications with de novo sirolimus versus mycophenolate mofetil-based regimen in cardiac transplant recipients. Am J Transplant 2006; 6 (5 Part 1): 986\u2013992.","journal-title":"Am J Transplant"},{"key":"BFbmt2011104_CR34","doi-asserted-by":"publisher","first-page":"505","DOI":"10.7326\/0003-4819-144-7-200604040-00009","volume":"144","author":"L Champion","year":"2006","unstructured":"Champion L, Stern M, Israel-Biet D, Mamzer-Bruneel MF, Peraldi MN, Kreis H et al. Brief communication: sirolimus-associated pneumonitis: 24 cases in renal transplant recipients. Ann Intern Med 2006; 144: 505\u2013509.","journal-title":"Ann Intern Med"},{"key":"BFbmt2011104_CR35","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1517\/14656566.2.11.1903","volume":"2","author":"BD Kahan","year":"2001","unstructured":"Kahan BD . Sirolimus: a comprehensive review. Expert Opin Pharmacother 2001; 2: 1903\u20131917.","journal-title":"Expert Opin Pharmacother"},{"key":"BFbmt2011104_CR36","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1097\/00007890-199904150-00017","volume":"67","author":"CG Groth","year":"1999","unstructured":"Groth CG, Backman L, Morales JM, Calne R, Kreis H, Lang P et al. Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group. Transplantation 1999; 67: 1036\u20131042.","journal-title":"Transplantation"},{"key":"BFbmt2011104_CR37","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1097\/00007890-200004150-00009","volume":"69","author":"H Kreis","year":"2000","unstructured":"Kreis H, Cisterne JM, Land W, Wramner L, Squifflet JP, Abramowicz D et al. Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients. Transplantation 2000; 69: 1252\u20131260.","journal-title":"Transplantation"},{"key":"BFbmt2011104_CR38","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/S0140-6736(00)02480-6","volume":"356","author":"BD Kahan","year":"2000","unstructured":"Kahan BD . Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study. The Rapamune US Study Group. Lancet 2000; 356: 194\u2013202.","journal-title":"Lancet"},{"key":"BFbmt2011104_CR39","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1097\/00007890-200101270-00019","volume":"71","author":"AS MacDonald","year":"2001","unstructured":"MacDonald AS . A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus\/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts. Transplantation 2001; 71: 271\u2013280.","journal-title":"Transplantation"},{"key":"BFbmt2011104_CR40","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1681\/ASN.V1251059","volume":"12","author":"H Podder","year":"2001","unstructured":"Podder H, Stepkowski SM, Napoli KL, Clark J, Verani RR, Chou TC et al. Pharmacokinetic interactions augment toxicities of sirolimus\/cyclosporine combinations. J Am Soc Nephrol 2001; 12: 1059\u20131071.","journal-title":"J Am Soc Nephrol"},{"key":"BFbmt2011104_CR41","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.bbmt.2008.02.009","volume":"14","author":"T Furlong","year":"2008","unstructured":"Furlong T, Kiem HP, Appelbaum FR, Carpenter PA, Deeg HJ, Doney K et al. Sirolimus in combination with cyclosporine or tacrolimus plus methotrexate for prevention of graft-versus-host disease following hematopoietic cell transplantation from unrelated donors. Biol Blood Marrow Transplant 2008; 14: 531\u2013537.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2011104_CR42","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.bbmt.2008.11.004","volume":"15","author":"U Platzbecker","year":"2009","unstructured":"Platzbecker U, von Bonin M, Goekkurt E, Radke J, Binder M, Kiani A et al. Graft-versus-host disease prophylaxis with everolimus and tacrolimus is associated with a high incidence of sinusoidal obstruction syndrome and microangiopathy: results of the EVTAC trial. Biol Blood Marrow Transplant 2009; 15: 101\u2013108.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2011104_CR43","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1182\/blood-2006-01-0329","volume":"108","author":"R Zeiser","year":"2006","unstructured":"Zeiser R, Nguyen VH, Beilhack A, Buess M, Schulz S, Baker J et al. Inhibition of CD4+CD25+ regulatory T-cell function by calcineurin-dependent interleukin-2 production. Blood 2006; 108: 390\u2013399.","journal-title":"Blood"},{"key":"BFbmt2011104_CR44","doi-asserted-by":"publisher","first-page":"e5994","DOI":"10.1371\/journal.pone.0005994","volume":"4","author":"L Strauss","year":"2009","unstructured":"Strauss L, Czystowska M, Szajnik M, Mandapathil M, Whiteside TL . Differential responses of human regulatory T cells (Treg) and effector T cells to rapamycin. PLoS One 2009; 4: e5994.","journal-title":"PLoS One"},{"key":"BFbmt2011104_CR45","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1182\/blood-2007-11-125542","volume":"112","author":"E Gatza","year":"2008","unstructured":"Gatza E, Rogers CE, Clouthier SG, Lowler KP, Tawara I, Liu C et al. Extracorporeal photopheresis reverses experimental graft-versus-host disease through regulatory T cells. Blood 2008; 112: 1515\u20131521.","journal-title":"Blood"},{"key":"BFbmt2011104_CR46","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1097\/01.tp.0000267785.52567.9c","volume":"84","author":"E Biagi","year":"2007","unstructured":"Biagi E, Di Biaso I, Leoni V, Gaipa G, Rossi V, Bugarin C et al. Extracorporeal photochemotherapy is accompanied by increasing levels of circulating CD4+CD25+GITR+Foxp3+CD62L+ functional regulatory T-cells in patients with graft-versus-host disease. Transplantation 2007; 84: 31\u201339.","journal-title":"Transplantation"},{"key":"BFbmt2011104_CR47","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1182\/blood-2006-02-003996","volume":"108","author":"K Rezvani","year":"2006","unstructured":"Rezvani K, Mielke S, Ahmadzadeh M, Kilical Y, Savani BN, Zeilah J et al. High donor FOXP3-positive regulatory T-cell (Treg) content is associated with a low risk of GVHD following HLA-matched allogeneic SCT. Blood 2006; 108: 1291\u20131297.","journal-title":"Blood"},{"key":"BFbmt2011104_CR48","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1182\/blood-2007-03-079160","volume":"110","author":"S Mielke","year":"2007","unstructured":"Mielke S, Rezvani K, Savani BN, Nunes R, Yong AS, Schindler J et al. Reconstitution of FOXP3+ regulatory T cells (Tregs) after CD25-depleted allotransplantation in elderly patients and association with acute graft-versus-host disease. Blood 2007; 110: 1689\u20131697.","journal-title":"Blood"},{"key":"BFbmt2011104_CR49","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/j.clpt.2005.08.009","volume":"78","author":"P Jacobson","year":"2005","unstructured":"Jacobson P, Rogosheske J, Barker JN, Green K, Ng J, Weisdorf D et al. Relationship of mycophenolic acid exposure to clinical outcome after hematopoietic cell transplantation. Clin Pharmacol Ther 2005; 78: 486\u2013500.","journal-title":"Clin Pharmacol Ther"},{"key":"BFbmt2011104_CR50","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1177\/0091270006295064","volume":"47","author":"P Jacobson","year":"2007","unstructured":"Jacobson P, Green K, Rogosheske J, Brunstein C, Ebeling B, DeFor T et al. Highly variable mycophenolate mofetil bioavailability following nonmyeloablative hematopoietic cell transplantation. J Clin Pharmacol 2007; 47: 6\u201312.","journal-title":"J Clin Pharmacol"},{"key":"BFbmt2011104_CR51","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/S0041-1345(98)01531-0","volume":"31","author":"MS Golconda","year":"1999","unstructured":"Golconda MS, Valente JF, Bejarano P, Gilinsky N, First MR . Mycophenolate mofetil-induced colonic ulceration in renal transplant recipients. Transplant Proc 1999; 31: 272\u2013273.","journal-title":"Transplant Proc"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/bmt2011104.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bmt2011104","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bmt2011104.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T13:18:06Z","timestamp":1648041486000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bmt2011104"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,5,9]]},"references-count":51,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,4]]}},"alternative-id":["BFbmt2011104"],"URL":"https:\/\/doi.org\/10.1038\/bmt.2011.104","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,5,9]]},"assertion":[{"value":"17 December 2010","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2011","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 March 2011","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2011","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}